The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
MeSH Review

Opioid-Related Disorders

 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Opioid-Related Disorders

 

Psychiatry related information on Opioid-Related Disorders

 

High impact information on Opioid-Related Disorders

 

Chemical compound and disease context of Opioid-Related Disorders

 

Biological context of Opioid-Related Disorders

 

Anatomical context of Opioid-Related Disorders

 

Gene context of Opioid-Related Disorders

  • This study reveals a cardinal role for CRF/CRF1 receptor pathways in the negative affective states of opiate withdrawal and suggests therapeutic strategies for the treatment of opiate addiction [28].
  • Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence [21].
  • The abnormalities of MAPK signalling might have important consequences in the long term development of various forms of neural plasticity associated with opiate addiction in humans [29].
  • The authors describe the use of moclobemide in a 27-year-old patient with comorbid opiate addiction and ADHD (residual type) [30].
  • In contrast to data obtained in adult animals, NMDA receptor antagonists are neither effective in blocking the development of opiate dependence nor the expression of opiate withdrawal in neonatal rats [31].
 

Analytical, diagnostic and therapeutic context of Opioid-Related Disorders

References

  1. Methadone maintenance treatment, criminality and overdose-related deaths. An ecological study, 1983-1999. Niveau, G., Rougemont, A.L., La Harpe, R. European journal of public health. (2002) [Pubmed]
  2. Character and meaning of quasi-morphine withdrawal phenomena elicited by methylxanthines. Collier, H.O., Cuthbert, N.J., Francis, D.L. Fed. Proc. (1981) [Pubmed]
  3. Therapeutic communities vs methadone maintenance. A prospective controlled study of narcotic addiction treatment: design and one-year follow-up. Bale, R.N., Van Stone, W.W., Kuldau, J.M., Engelsing, T.M., Elashoff, R.M., Zarcone, V.P. Arch. Gen. Psychiatry (1980) [Pubmed]
  4. Integrating the cognitive and physiological aspects of craving. Weinstein, A., Feldtkeller, B., Malizia, A., Wilson, S., Bailey, J., Nutt, D.J. J. Psychopharmacol. (Oxford) (1998) [Pubmed]
  5. Prevention of morphine-induced muscarinic (M2) receptor adaptation suppresses the expression of withdrawal symptoms. Zhang, L.C., Buccafusco, J.J. Brain Res. (1998) [Pubmed]
  6. Comparing assessments of DSM-IV substance dependence disorders using CIDI-SAM and SCAN. Compton, W.M., Cottler, L.B., Dorsey, K.B., Spitznagel, E.L., Mager, D.E. Drug and alcohol dependence. (1996) [Pubmed]
  7. Concordance of DSM-IV alcohol and drug use disorder criteria and diagnoses as measured by AUDADIS-ADR, CIDI and SCAN. Cottler, L.B., Grant, B.F., Blaine, J., Mavreas, V., Pull, C., Hasin, D., Compton, W.M., Rubio-Stipec, M., Mager, D. Drug and alcohol dependence. (1997) [Pubmed]
  8. Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Kreek, M.J., Bart, G., Lilly, C., LaForge, K.S., Nielsen, D.A. Pharmacol. Rev. (2005) [Pubmed]
  9. Reduction of morphine abstinence in mice with a mutation in the gene encoding CREB. Maldonado, R., Blendy, J.A., Tzavara, E., Gass, P., Roques, B.P., Hanoune, J., Schütz, G. Science (1996) [Pubmed]
  10. Altered neuroadaptation in opiate dependence and neurogenic inflammatory nociception in alpha CGRP-deficient mice. Salmon, A.M., Damaj, M.I., Marubio, L.M., Epping-Jordan, M.P., Merlo-Pich, E., Changeux, J.P. Nat. Neurosci. (2001) [Pubmed]
  11. Controlled clinical evaluation of diacetyl morphine for treatment of intractable opiate dependence. Drucker, E., Vlahov, D. Lancet (1999) [Pubmed]
  12. Cortical and limbic dopamine (on opiate addiction): do not mix before use! Di Chiara, G. Trends Pharmacol. Sci. (1997) [Pubmed]
  13. Therapeutic usefulness of propoxyphene napsylate in narcotic addiction. Jasinski, D.R., Pevnick, J.S., Clark, S.C., Griffith, J.D. Arch. Gen. Psychiatry (1977) [Pubmed]
  14. Evaluation of propranolol in opiate dependence. Resnick, R.B., Kestenbaum, R.S., Schwartz, L.K., Smith, A. Arch. Gen. Psychiatry (1976) [Pubmed]
  15. Dual regulation of adenylate cyclase accounts for narcotic dependence and tolerance. Sharma, S.K., Klee, W.A., Nirenberg, M. Proc. Natl. Acad. Sci. U.S.A. (1975) [Pubmed]
  16. Pathological gambling among cocaine-dependent outpatients. Hall, G.W., Carriero, N.J., Takushi, R.Y., Montoya, I.D., Preston, K.L., Gorelick, D.A. The American journal of psychiatry. (2000) [Pubmed]
  17. A clinical, controlled study of l-alpha-acetylmethadol in the treatment of narcotic addiction. Marcovici, M., O'Brien, C.P., McLellan, A.T., Kacian, J. The American journal of psychiatry. (1981) [Pubmed]
  18. CREB (cAMP response element-binding protein) in the locus coeruleus: biochemical, physiological, and behavioral evidence for a role in opiate dependence. Lane-Ladd, S.B., Pineda, J., Boundy, V.A., Pfeuffer, T., Krupinski, J., Aghajanian, G.K., Nestler, E.J. J. Neurosci. (1997) [Pubmed]
  19. Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. Friedland, G., Andrews, L., Schreibman, T., Agarwala, S., Daley, L., Child, M., Shi, J., Wang, Y., O'Mara, E. AIDS (2005) [Pubmed]
  20. Downregulation of neuronal cdk5/p35 in opioid addicts and opiate-treated rats: relation to neurofilament phosphorylation. Ferrer-Alcón, M., La Harpe, R., Guimón, J., García-Sevilla, J.A. Neuropsychopharmacology (2003) [Pubmed]
  21. Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. Tyndale, R.F., Droll, K.P., Sellers, E.M. Pharmacogenetics (1997) [Pubmed]
  22. Galanin can attenuate opiate reinforcement and withdrawal. Picciotto, M.R., Hawes, J.J., Brunzell, D.H., Zachariou, V. Neuropeptides (2005) [Pubmed]
  23. Regulation of expression of cAMP response element-binding protein in the locus coeruleus in vivo and in a locus coeruleus-like cell line in vitro. Widnell, K.L., Russell, D.S., Nestler, E.J. Proc. Natl. Acad. Sci. U.S.A. (1994) [Pubmed]
  24. Opioid peptide biosynthesis: enzymatic selectivity and regulatory mechanisms. Costa, E., Mocchetti, I., Supattapone, S., Snyder, S.H. FASEB J. (1987) [Pubmed]
  25. Mean red blood cell volume, narcotic addiction, and glucose tolerance. Cerièllo, A., Dello Russo, P., Curcio, F., Passariello, N., Giugliano, D. Arch. Intern. Med. (1985) [Pubmed]
  26. Long-lasting reciprocal changes in striatal dopamine and acetylcholine release upon morphine withdrawal. Tjon Tien Ril, H.K., De Vries, T.J., Wardeh, G., Hogenboom, F., Mulder, A.H., Schoffelmeer, A.N. Eur. J. Pharmacol. (1993) [Pubmed]
  27. Cyclophosphamide and cortisol reduce the severity of morphine withdrawal. Montgomery, S.P., Dafny, N. Int. J. Immunopharmacol. (1987) [Pubmed]
  28. The corticotropin-releasing factor receptor-1 pathway mediates the negative affective states of opiate withdrawal. Contarino, A., Papaleo, F. Proc. Natl. Acad. Sci. U.S.A. (2005) [Pubmed]
  29. Long-term regulation of signalling components of adenylyl cyclase and mitogen-activated protein kinase in the pre-frontal cortex of human opiate addicts. Ferrer-Alcón, M., J García-Fuster, M., La Harpe, R., García-Sevilla, J.A. J. Neurochem. (2004) [Pubmed]
  30. Treatment of comorbid opiate addiction and attention-deficit hyperactivity disorder (residual type) with moclobemide: a case report. Vaiva, G., De Lenclave, M.B., Bailly, D. Prog. Neuropsychopharmacol. Biol. Psychiatry (2002) [Pubmed]
  31. Opiate physical dependence and N-methyl-D-aspartate receptors. Noda, Y., Nabeshima, T. Eur. J. Pharmacol. (2004) [Pubmed]
  32. Increased density of guanine nucleotide-binding proteins in the postmortem brains of heroin addicts. Escriba, P.V., Sastre, M., Garcia-Sevilla, J.A. Arch. Gen. Psychiatry (1994) [Pubmed]
  33. Opiates, opioids and addiction. Kreek, M.J. Mol. Psychiatry (1996) [Pubmed]
  34. Chronic neuroleptic treatment and mesolimbic dopamine denervation induce behavioural supersensitivity to opiates. Stinus, L., Winnock, M., Kelley, A.E. Psychopharmacology (Berl.) (1985) [Pubmed]
  35. Basal signaling activity of mu opioid receptor in mouse brain: role in narcotic dependence. Wang, D., Raehal, K.M., Lin, E.T., Lowery, J.J., Kieffer, B.L., Bilsky, E.J., Sadée, W. J. Pharmacol. Exp. Ther. (2004) [Pubmed]
  36. Effects of 2beta-propanoyl-3beta-(4-tolyl)-tropane (PTT) on the self-administration of cocaine, heroin, and cocaine/heroin combinations in rats. Sizemore, G.M., Davies, H.M., Martin, T.J., Smith, J.E. Drug and alcohol dependence. (2004) [Pubmed]
 
WikiGenes - Universities